RHHBY - Roche Holding AG

Other OTC - Other OTC Delayed Price. Currency in USD
30.60
+0.05 (+0.16%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Previous Close30.55
Open30.45
Bid0.00 x 0
Ask0.00 x 0
Day's Range30.44 - 30.65
52 Week Range26.30 - 32.42
Volume412,610
Avg. Volume1,118,617
Market Cap206.469B
Beta0.47
PE Ratio (TTM)19.93
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield1.08 (3.50%)
Ex-Dividend Date2018-03-15
1y Target EstN/A
Trade prices are not sourced from all markets
  • Novo Nordisk to Restructure R&D Unit & Lay Off 400 Staff
    Zacks2 days ago

    Novo Nordisk to Restructure R&D Unit & Lay Off 400 Staff

    Novo Nordisk (NVO) plans to restructure and reallocate resources in its Research and Development organization and lay off 400 employees from the unit.

  • Bayer (BAYRY) Focuses on Acquisitions, Competition a Concern
    Zacks3 days ago

    Bayer (BAYRY) Focuses on Acquisitions, Competition a Concern

    Bayer (BAYRY) focuses on acquisitions and deals in order to boost growth as well as portfolio.

  • Pfizer's Skin Disease Candidates Positive in Mid-Stage Study
    Zacks3 days ago

    Pfizer's Skin Disease Candidates Positive in Mid-Stage Study

    Pfizer's (PFE) JAK inhibitor candidates -- PF-06651600 and PF-06700841 -- demonstrate improvements in moderate to severe alopecia areata patients in a phase II study.

  • Is Artificial Intelligence the Next Big Thing in Biotech?
    Zacks4 days ago

    Is Artificial Intelligence the Next Big Thing in Biotech?

    Artificial intelligence can drastically reduce the time taken to develop new life-saving drugs.

  • How Is Merck’s Keytruda Positioned in September?
    Market Realist4 days ago

    How Is Merck’s Keytruda Positioned in September?

    Merck’s (MRK) Keytruda has witnessed ~89% YoY (year-over-year) growth and generated second-quarter revenues of $1.7 billion. In the US market, Keytruda’s second-quarter revenues grew 73.0% to reach $959.0.0 million. In the international markets, Keytruda’s revenues increased ~118.0% YoY to reach $707.0.0 million.

  • Roche's Child Arthritis Drug's New Formulation Gets FDA Nod
    Zacks6 days ago

    Roche's Child Arthritis Drug's New Formulation Gets FDA Nod

    Roche (RHHBY) gets FDA approval for the subcutaneous formulation of Actemra for the treatment of active systemic juvenile idiopathic arthritis in patients aged two years or older.

  • AstraZeneca's Lumoxiti Gets FDA Nod for Hairy Cell Leukemia
    Zacks6 days ago

    AstraZeneca's Lumoxiti Gets FDA Nod for Hairy Cell Leukemia

    AstraZeneca's (AZN) rare blood cancer candidate receives approval from the FDA for relapsed or refractory hairy cell leukemia (HCL) in patients who have received at least two prior systemic therapies.

  • Johnson & Johnson Expands Blood Cancer Portfolio with Approval
    Market Realist7 days ago

    Johnson & Johnson Expands Blood Cancer Portfolio with Approval

    On August 27, Johnson & Johnson (JNJ) announced that it received FDA approval for its combination therapy of Imbruvica and Roche’s (RHHBY) rituximab for the treatment of WM (Waldenström’s macroglobulinemia), a rare blood cancer. According to JNJ, ~2,800 new WM cases are reported each year in the United States.

  • Reuters7 days ago

    Roche steps up efficiency drive to take sting out of biosimilars

    LONDON/ZURICH (Reuters) - Roche, the world's biggest producer of cancer drugs, is stepping up cost cuts in an efficiency drive made unavoidable by competition from cut-price copies of three mega-brands from its famed U.S. Genentech biotech stable. Chief Executive Severin Schwan told Reuters he was confident he could fill the sales gap but expects only "moderate growth" into 2019 - helped by newer drugs such as Ocrevus for multiple sclerosis (MS) - before a "re-acceleration" around 2021-22. "If you have such a sharp portfolio shift as we have now, then of course you have to reallocate resources in a more dramatic way," Schwan said.

  • Roche steps up efficiency drive to take sting out of biosimilars
    Reuters7 days ago

    Roche steps up efficiency drive to take sting out of biosimilars

    LONDON/ZURICH (Reuters) - Roche (ROG.S), the world's biggest producer of cancer drugs, is stepping up cost cuts in an efficiency drive made unavoidable by competition from cut-price copies of three mega-brands from its famed U.S. Genentech biotech stable. Chief Executive Severin Schwan told Reuters he was confident he could fill the sales gap but expects only "moderate growth" into 2019 - helped by newer drugs such as Ocrevus for multiple sclerosis (MS) - before a "re-acceleration" around 2021-22. "If you have such a sharp portfolio shift as we have now, then of course you have to reallocate resources in a more dramatic way," Schwan said.

  • Roche boss says Brexit and curbs on drug use pose threat to UK science
    Reuters7 days ago

    Roche boss says Brexit and curbs on drug use pose threat to UK science

    Uncertainty over drug regulation and a reluctance by Britain's health service to use certain pricey modern medicines pose a threat to the country's respected life sciences sector, the head Swiss drugmaker Roche (ROG.S) said on Thursday. With only six months to go until the United Kingdom is due to leave the European Union, the highly regulated pharmaceuticals industry still does not know exactly how medicines oversight will function. Severin Schwan, chief executive of the world's biggest maker of cancer drugs, said in an interview that Europe was already slower than the United States to approve new medicines and there are fears the UK might fall further behind, jeopardising investment.

  • Reuters8 days ago

    Roche boss says Brexit and curbs on drug use pose threat to UK science

    Uncertainty over drug regulation and a reluctance by Britain's health service to use certain pricey modern medicines pose a threat to the country's respected life sciences sector, the head Swiss drugmaker Roche said on Thursday. With only six months to go until the United Kingdom is due to leave the European Union, the highly regulated pharmaceuticals industry still does not know exactly how medicines oversight will function. Severin Schwan, chief executive of the world's biggest maker of cancer drugs, said in an interview that Europe was already slower than the United States to approve new medicines and there are fears the UK might fall further behind, jeopardising investment.

  • Bloomberg8 days ago

    Roche CEO Slams U.K. Health System for Slowing Innovation

    Roche Holding AG Chief Executive Officer Severin Schwan blasted a U.K. decision not to pay for one of the company’s blockbuster drugs to treat a rare form of multiple sclerosis, saying it would restrict innovation. The ruling by the U.K.’s National Institute for Health and Care Excellence is part of an antiquated approach to drug evaluation that’s “appalling” and “deeply needs to be overhauled” if pharmaceutical companies are going to invest money in the country, Schwan said Thursday in an interview in London. The CEO’s critique comes as the U.K. faces potential threats to drug supplies, research funding and access to trained personnel in light of Brexit.

  • Motley Fool8 days ago

    3 Lung Cancer Stocks That Could End September on a High Note

    This year's World Conference on Lung Cancer has some important presentations scheduled.

  • Roche CEO Refuses to Cede Cancer's Hottest New Field to Merck
    Bloomberg8 days ago

    Roche CEO Refuses to Cede Cancer's Hottest New Field to Merck

    Roche Holding AG is refusing to cede the hottest new area of cancer care to Merck & Co. despite trailing its U.S. rival. Merck’s immune therapy Keytruda has dominated the market, with analysts predicting it will deliver more than $10 billion in annual sales by 2020. Roche still believes it can be a leader in the field of drugs designed to unleash the body’s immune system against tumors, with positive results for its own contender Tecentriq coming at two conferences this fall, Chief Executive Officer Severin Schwan said in an interview.

  • The Zacks Analyst Blog Highlights: Oracle, Roche, Goldman Sachs, Capital One and Intercontinental Exchange
    Zacks8 days ago

    The Zacks Analyst Blog Highlights: Oracle, Roche, Goldman Sachs, Capital One and Intercontinental Exchange

    The Zacks Analyst Blog Highlights: Oracle, Roche, Goldman Sachs, Capital One and Intercontinental Exchange

  • Roche CEO Sees Good Demand for New Medicines
    Bloomberg8 days ago

    Roche CEO Sees Good Demand for New Medicines

    Severin Schwan, chief executive officer at Roche, discusses the company’s acquisition strategy, preparations for Brexit, and the potential impact of a trade war. He speaks with Bloomberg's Nejra Cehic ...

  • Zacks8 days ago

    Top Research Reports for Oracle, Roche & Goldman Sachs

    Top Research Reports for Oracle, Roche & Goldman Sachs

  • AbbVie Gets FDA Nod for Venclexta Label Expansion in Leukemia
    Zacks8 days ago

    AbbVie Gets FDA Nod for Venclexta Label Expansion in Leukemia

    AbbVie (ABBV) gets FDA approval to include MRD-negativity (undetectable disease) data from phase III MURANO study on the label of Venclexta.

  • Immunotherapy for NSCLC: 4 Large-Cap Pharma Stocks in Focus
    Zacks8 days ago

    Immunotherapy for NSCLC: 4 Large-Cap Pharma Stocks in Focus

    Here we take a look at companies with approved immunotherapy therapies or pipeline candidates for the treatment of widely prevalent NSCLC.

  • Bristol-Myers (BMY) Reports Phase II Data on Psoriasis Drug
    Zacks8 days ago

    Bristol-Myers (BMY) Reports Phase II Data on Psoriasis Drug

    Bristol-Myers Squibb (BMY) announces encouraging data from a phase II study on plaque psoriasis candidate.

  • Reuters11 days ago

    Roche faces UK pricing row over multiple sclerosis drug Ocrevus

    Roche (ROG.S) faces a fresh row over drug pricing in Britain, following a decision by the body responsible for medicine use within the state health service not to approve its drug Ocrevus for treating a highly disabling form of multiple sclerosis (MS). In June, the National Institute for Health and Care Excellence (NICE) endorsed Ocrevus for relapsing-remitting MS - the most common type of the disease - but it has now rejected it for the rarer and more severe primary-progressive form of MS. Ocrevus is the only available treatment for primary-progressive MS (PPMS), while there are several drugs for relapsing-remitting MS (RRMS), and Roche UK general manager Richard Erwin said Monday's decision was "devastating news" for patients.

  • Roche faces UK pricing row over multiple sclerosis drug Ocrevus
    Reuters11 days ago

    Roche faces UK pricing row over multiple sclerosis drug Ocrevus

    Roche faces a fresh row over drug pricing in Britain, following a decision by the body responsible for medicine use within the state health service not to approve its drug Ocrevus for treating a highly disabling form of multiple sclerosis (MS). In June, the National Institute for Health and Care Excellence (NICE) endorsed Ocrevus for relapsing-remitting MS - the most common type of the disease - but it has now rejected it for the rarer and more severe primary-progressive form of MS. Ocrevus is the only available treatment for primary-progressive MS (PPMS), while there are several drugs for relapsing-remitting MS (RRMS), and Roche UK general manager Richard Erwin said Monday's decision was "devastating news" for patients.

  • Pharma Stock Roundup: NVS' Sandoz Deal, Pipeline Updates at AZN & Others in Focus
    Zacks13 days ago

    Pharma Stock Roundup: NVS' Sandoz Deal, Pipeline Updates at AZN & Others in Focus

    Novartis (NVS) to sell parts of its Sandoz Unit. AstraZeneca (AZN), Merck (MRK), Pfizer (PFE) and others announce pipeline and regulatory updates.

  • Roche CEO Sees Good Demand for New Medicines
    Bloomberg Video8 days ago

    Roche CEO Sees Good Demand for New Medicines

    Sep.13 -- Severin Schwan, chief executive officer at Roche, discusses the company’s acquisition strategy, preparations for Brexit, and the potential impact of a trade war. He speaks with Bloomberg's Nejra Cehic on "Bloomberg Surveillance."